文献速递药物不良反应与药物警戒

多医院前后对照观察研究:输液安全干预组合对减少静脉给药差错的效果

A Multi-hospital Before-After Observational Study Using a Point-Prevalence Approach with an Infusion Safety Intervention Bundle to Reduce Intravenous Medication Administration Errors.
PubMed 文献 · Drug Saf · 2018-01-01

在9家医院开展前瞻性点患病率前后对照观察,评估输液安全干预组合对静脉给药差错的影响。干预前418例患者972次给药,干预后422例患者1059次给药。总体差错率从每100次给药146次降至123次,用药差错率从39次降至29次,但潜在有害差错率无显著变化。

要点

  • 输液安全干预组合可降低总体差错率和用药差错率。
  • 潜在有害差错率干预前后无显著变化。
  • 仅减少标签未完成差错的干预组分有效,其他组分未显著改善目标差错。

核心结论

  • 输液安全干预组合的开发与实施成功降低了总体差错率和用药差错率。
  • 部分差错仍然存在,潜在有害差错率未发生变化。
  • 差错率下降并不总是与特定单项干预相关。

研究设计与样本

  • 在9家医院开展的前后对照观察研究,采用前瞻性点患病率方法。
  • 干预前阶段评估418例患者共972次给药,干预后阶段评估422例患者共1059次给药。
  • 主要结局为总体差错率和用药差错率,次要结局为潜在有害差错率。

主要发现

  • 总体差错率从每100次给药146次降至123次(p < 0.0001)。
  • 用药差错率从每100次给药39次降至29次(p = 0.001)。
  • 潜在有害差错率从每100次给药0.5次变为0.8次,无显著变化(p = 0.37)。
  • 旨在减少标签未完成差错的干预组分有效降低了目标差错率,但干预组合的其他组分未显著改善其目标差错。

临床怎么用

  • 可参考该干预组合降低静脉给药总体差错率和用药差错率。
  • 需关注潜在有害差错未随干预下降,应持续监测并针对性改进。
  • 单项干预与差错率下降的关联不一致,实施时需评估各组分实际效果。

局限性

  • 研究为前后对照观察设计,非随机对照,因果推断受限。
  • 仅评估初步效果,需进一步研究确定减少剩余差错的最佳策略。
  • 潜在有害差错率事件数可能较少,需谨慎解读其无显著变化的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We previously found a high rate of errors in the administration of intravenous medications using smart infusion pumps. OBJECTIVES/DESIGN: An infusion safety intervention bundle was developed in response to the high rate of identified errors. A before-after observational study with a prospective point-prevalence approach was conducted in nine hospitals to measure the preliminary effects of the intervention. MAIN OUTCOME MEASURES: Primary outcome measures were overall errors and medication errors, with the secondary outcome defined as potentially harmful error rates. RESULTS: We assessed a total of 418 patients with 972 medication administrations in the pre-intervention period and 422 patients with 1059 medication administrations in the post-intervention period. The overall error rate fell from 146 to 123 per 100 medication administrations (p < 0.0001), and the medication error rate also decreased from 39 to 29 per 100 medication administrations (p = 0.001). However, there was no significant change in the potentially harmful error rate (from 0.5 to 0.8 per 100 medication administrations, p = 0.37). An intervention component aiming to reduce labeling-not-completed errors was effective in reducing targeted error rates, but other components of the intervention bundle did not show significant improvement in the targeted errors. CONCLUSION: Development and implementation of the intervention bundle was successful at reducing overall and medication error rates, but some errors remained and the potentially harmful error rate did not change. The error-rate reductions were not always correlated with the specific individual interventions. Further investigation is needed to identify the best strategies to reduce the remaining errors. CLINICAL TRIALS REGISTRATION: Registered at ClinicalTrials.gov, identifier: NCT02359734.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Schnock KO, Dykes PC, Albert J, et al. A Multi-hospital Before-After Observational Study Using a Point-Prevalence Approach with an Infusion Safety Intervention Bundle to Reduce Intravenous Medication Administration Errors. Drug Saf. 2018. PMID: 29411338. doi:10.1007/s40264-018-0637-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。